Global Ingredient Risk Index Botanical

Curcumin Phytosome

Curcuma longa

Also known as: Meriva, Phosphatidylcholine-curcumin complex, Bioavailable curcumin

27 მარ 2026

LOW RISK 2.5/10 How?

This ingredient is classified as unclassified risk (GIRI score: 2.5/10).

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->

Information not yet available for this ingredient profile.

Curcumin phytosome (e.g., Meriva) is a phosphatidylcholine complex that significantly increases curcumin bioavailability compared to standard turmeric extract. Its safety profile mirrors curcumin but with potentially greater systemic exposure. GI discomfort at high doses is the main side effect. The increased bioavailability may amplify interactions with CYP3A4-metabolised drugs including anticoagulants. Use with caution in patients on warfarin, chemotherapy, or immunosuppressants.

Scientific Name: Curcuma longa

Information not yet available for this ingredient profile.

SETI Score 50/100

Risk Level High risk

Scientific Confidence Low

Evidence Strength Limited

Key Benefit Botanical

Evidence Reviewed 10 PubMed studies

Scientific Confidence Low

Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100

Risk Level High risk

Evidence Strength Limited

Main Benefit Botanical

Ingredient Curcumin Phytosome

Scientific name Curcuma longa

Scientific Evidence Overview

10 studies reviewed
0 high-quality studies (meta-analysis or RCT)
Main clinical benefit observed: Botanical
Evidence consistency: High consistency across studies (100%)

Safety Signals

No significant safety signals identified in the reviewed literature.

Evidence Strength Limited

Final Scientific Assessment

The available scientific evidence for Curcumin Phytosome indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Curcumin Phytosome

Evidence reviewed 10 peer-reviewed studies (last 10 years)

Scientific name Curcuma longa

50 /100

Total SETI Score

High risk

Evidence quality	10/40
Evidence consistency	20/20
Safety signals	0/20
Study recency	10/10
Evidence transparency	10/10

Evidence Summary

10 studies reviewed
0 high-quality studies (meta-analysis or systematic review)
0 studies identified benefits or no safety concern (GREEN)
10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 26 მარ 2026, 14:07

Evidence Distribution

10 Other / unclassified

Observational / other LOW evidence YELLOW
Optimization of the extraction of Curcuma longa L. oleoresin with supercritical CO2. ↗

PMID 41880396 ↗

Journal An Acad Bras Cienc

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41880396/

Barriga-Su00e1nchez M et al.. Optimization of the extraction of Curcuma longa L. oleoresin with supercritical CO2.. An Acad Bras Cienc. 2026. PMID:41880396.
Observational / other LOW evidence YELLOW
Curcumin in Behu00e7et's disease: exploring therapeutic potential, evidence, and key research gaps. ↗

PMID 41879901 ↗

Journal Inflammopharmacology

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41879901/

Heidari Z et al.. Curcumin in Behu00e7et's disease: exploring therapeutic potential, evidence, and key research gaps.. Inflammopharmacology. 2026. PMID:41879901.
Observational / other LOW evidence YELLOW
Curcumin Nanocrystals: Synthesis, Optimisation and Prospects of Anticancer Activity Against Primarily Female-Associated Cancers. ↗

PMID 41878136 ↗

Journal Int J Nanomedicine

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41878136/

Ndongwe T et al.. Curcumin Nanocrystals: Synthesis, Optimisation and Prospects of Anticancer Activity Against Primarily Female-Associated Cancers.. Int J Nanomedicine. 2026. PMID:41878136.
Observational / other LOW evidence YELLOW
Curcumin: A Multifunctional Molecule for the Detection of Various Adulterants, Pathogens, and Toxins in the Agro-Food Industry. ↗

PMID 41877454 ↗

Journal Compr Rev Food Sci Food Saf

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41877454/

Gupta KK et al.. Curcumin: A Multifunctional Molecule for the Detection of Various Adulterants, Pathogens, and Toxins in the Agro-Food Industry.. Compr Rev Food Sci Food Saf. 2026. PMID:41877454.
Observational / other LOW evidence YELLOW
CHARMM Force Field for Curcuma longa Phytochemicals: Towards Reliable Modeling of Curcuminoids and Turmerones in Biological Systems. ↗

PMID 41858136 ↗

Journal J Comput Chem

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41858136/

Archana et al.. CHARMM Force Field for Curcuma longa Phytochemicals: Towards Reliable Modeling of Curcuminoids and Turmerones in Biological Systems.. J Comput Chem. 2026. PMID:41858136.
Observational / other LOW evidence YELLOW
Curcuma longa-derived extracellular vesicle-like particles ameliorate retinal neovascularization through HIF-1u03b1 and NRF2 signaling. ↗

PMID 41851718 ↗

Journal J Nanobiotechnology

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41851718/

Chen Y et al.. Curcuma longa-derived extracellular vesicle-like particles ameliorate retinal neovascularization through HIF-1u03b1 and NRF2 signaling.. J Nanobiotechnology. 2026. PMID:41851718.
Observational / other LOW evidence YELLOW
Phytomedicines and conventional drugs in scabies management. ↗

PMID 41835968 ↗

Journal GMS Hyg Infect Control

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41835968/

Hoque M. Phytomedicines and conventional drugs in scabies management.. GMS Hyg Infect Control. 2026. PMID:41835968.
Observational / other LOW evidence YELLOW
Integrated In silico and In vitro Screening of Phytoconstituents as Potential Inhibitors of New Delhi Metallo-u03b2-lactamase-1 (NDM-1). ↗

PMID 41830576 ↗

Journal Curr Pharm Biotechnol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41830576/

Kumar A et al.. Integrated In silico and In vitro Screening of Phytoconstituents as Potential Inhibitors of New Delhi Metallo-u03b2-lactamase-1 (NDM-1).. Curr Pharm Biotechnol. 2026. PMID:41830576.
Observational / other LOW evidence YELLOW
Stair-climbing resistance exercise, with or without oral turmeric (Curcuma longa L.) supplementation, relieves symptoms and promotes musculoskeletal repair in experimental rheumatoid arthritis… ↗

PMID 41824114 ↗

Journal J Muscle Res Cell Motil

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41824114/

Kuhn MG et al.. Stair-climbing resistance exercise, with or without oral turmeric (Curcuma longa L.) supplementation, relieves symptoms and promotes musculoskeletal repair in experimental rheumatoid arthritis in rats.. J Muscle Res Cell Motil. 2026. PMID:41824114.
Observational / other LOW evidence YELLOW
Curcumin in oral health: mechanisms, clinical evidence, and delivery strategies. ↗

PMID 41846867 ↗

Journal Front Pharmacol

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41846867/

Hu C et al.. Curcumin in oral health: mechanisms, clinical evidence, and delivery strategies.. Front Pharmacol. 2025. PMID:41846867.

Q × L × D × S × 10 = 2.5 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

Benefit

Risk

50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 2.5 / 10

Final GIRI Score for Curcumin Phytosome. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.

LOW RISK 2.5/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0

MODERATE
3.0–5.5

HIGH
5.5–7.5

CRITICAL
7.5–10

2.5

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Curcumin Phytosome

A score of 2.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

0 approved references.

Limited — mostly case reports or animal studies (Level 4–5).

Neutral or mixed — benefit and risk signals roughly balanced.

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

Level	Score	Meaning
LOW	0.0 – 2.9	Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE	3.0 – 5.4	Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH	5.5 – 7.4	Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL	7.5 – 10	Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

Curcumin Phytosome

Safety Profile

Interactions

Evidence and Scientific Findings

Ingredient Overview

Biological and Chemical Classification

Mechanism of Action

Clinical Evidence of Effectiveness

Pharmacokinetics

Recommended Dosage

SETI — Scientific Evidence Transparency Index

Executive Summary — Ingredient Assessment

Evidence Summary

Evidence Policy

Evidence Distribution

Score Transparency

Risk Level Classification

What drove the Low classification for Curcumin Phytosome

ბოლო სიახლეები

500მლ პლასტმასის წყლის ბოთლები: ფარული საზოგადოებრივი ჯანმრთელობის რისკები

სკოლამდელი განათლება – მნიშვნელობა და გამოწვევები

ბავშვის უფლებები სკოლაში

პოპულარული ამბები

საუკეთესო ფილმები კულინარიის მოყვარულებისთვის

როგორ იყენებენ ახალგაზრდები ხელოვნურ ინტელექტს – სტუდენტების ხმა

კატეგორიები

ჩვენ შესახებ

გამოგვყევი სოციალურ ქსელებში